Orchid receives FDA OK for Cephalexin oral suspension abbreviated NDA

By Elaine Rigoli

Tampa, Fla., July 12 - Orchid Chemicals & Pharmaceuticals, Ltd. has received Food and Drug Administration approval for its abbreviated New Drug Application of Cephalexin oral suspension.

Cephalexin is an off-patent molecule that forms part of the Orchid's distribution alliance with U.S. generic pharma major, Par Pharmaceuticals, Inc.

Orchid said that, given the complexity of the formulation, it would have a good positioning in the generics market. Orchid's Cephalexin capsules are already marketed in the U.S. distribution partnership with Par Pharmaceuticals.

Orchid is a global pharmaceutical company with headquarters in Tamil Nadu, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.